261 related articles for article (PubMed ID: 6951582)
1. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Olsson AG; Orö L
Atherosclerosis; 1982 Apr; 42(2-3):229-43. PubMed ID: 6951582
[TBL] [Abstract][Full Text] [Related]
2. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
Noseda G; Fragiacomo C; Weidmann P; Bachmann C
Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
Turpin G; Bruckert E
Atherosclerosis; 1996 Jul; 124 Suppl():S83-7. PubMed ID: 8831920
[TBL] [Abstract][Full Text] [Related]
4. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
[TBL] [Abstract][Full Text] [Related]
5. Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinanemia.
Olsson AG; Lang PD
Atherosclerosis; 1978 Dec; 31(4):421-8. PubMed ID: 215174
[TBL] [Abstract][Full Text] [Related]
6. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
Guerin M; Le Goff W; Frisdal E; Schneider S; Milosavljevic D; Bruckert E; Chapman MJ
J Clin Endocrinol Metab; 2003 Aug; 88(8):3738-46. PubMed ID: 12915663
[TBL] [Abstract][Full Text] [Related]
7. One-year study of the effect of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Olsson AG; Lang PD
Atherosclerosis; 1978 Dec; 31(4):429-33. PubMed ID: 215175
[TBL] [Abstract][Full Text] [Related]
8. Elevation of high density lipoprotein cholesterol (cHDL) and reduction of the total cholesterol/cHDL index in the treatment of hyperlipoproteinaemias IIb and IV with bezafibrate.
Neuman MP; Kurlat MI; Neuman J
Curr Med Res Opin; 1983; 8(5):358-67. PubMed ID: 6839800
[TBL] [Abstract][Full Text] [Related]
9. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
[TBL] [Abstract][Full Text] [Related]
10. Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate.
Rössner S; Orö L
Atherosclerosis; 1981; 38(3-4):273-82. PubMed ID: 7225166
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study.
Cattin L; Da Col PG; Feruglio FS; Finazzo L; Rimondi S; Descovich G; Manzato E; Zambon S; Crepaldi G; Siepi D
Clin Ther; 1990; 12(6):482-8. PubMed ID: 2289217
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B.
Rouffy J; Chanu B; Bakir R; Djian F; Goy-Loeper J
Atherosclerosis; 1985 Mar; 54(3):273-81. PubMed ID: 3994783
[TBL] [Abstract][Full Text] [Related]
13. Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
Hunninghake DB; Peters JR
Am J Med; 1987 Nov; 83(5B):44-9. PubMed ID: 3318453
[TBL] [Abstract][Full Text] [Related]
14. Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia.
Gavish D; Oschry Y; Fainaru M; Eisenberg S
Eur J Clin Invest; 1986 Feb; 16(1):61-8. PubMed ID: 3084275
[TBL] [Abstract][Full Text] [Related]
15. Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects.
Stewart JM; Packard CJ; Lorimer AR; Boag DE; Shepherd J
Atherosclerosis; 1982 Sep; 44(3):355-65. PubMed ID: 6293516
[TBL] [Abstract][Full Text] [Related]
16. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
Kontopoulos AG; Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Mayroudi MC; Boudoulas H
Coron Artery Dis; 1996 Nov; 7(11):843-50. PubMed ID: 8993943
[TBL] [Abstract][Full Text] [Related]
17. Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia.
Schwandt P; Weisweiler P; Drosner M; Janetschek P
Atherosclerosis; 1982 Apr; 42(2-3):245-9. PubMed ID: 7073803
[No Abstract] [Full Text] [Related]
18. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R
Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951
[TBL] [Abstract][Full Text] [Related]
19. Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrate.
Mordasini R; Riesen W; Oster P; Keller M; Middelhoff G; Lang PD
Atherosclerosis; 1981 Oct; 40(2):153-8. PubMed ID: 6796096
[TBL] [Abstract][Full Text] [Related]
20. Fenofibrate therapy of hypertriglyceridaemia. Differential effects on LDL cholesterol level in type IV and in type IIb primary hyperlipoproteinaemia.
Sommariva D; Bonfiglioli D; Pogliaghi I; Ottomano C; Fasoli A
Eur J Clin Pharmacol; 1984; 26(6):741-4. PubMed ID: 6489413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
